Wednesday, June 09, 2021
Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced today its partnership with GenScript ProBio, the biopharmaceutical contract research organization (CRO) and contract development and manufacturing organization (CDMO) segment of the global biotechnology company, GenScript, Inc., for assistance in the advertisement and distribution of Calidi’s proprietary technology platform: SuperNova-1 (SNV-1). The SNV-1 platform is composed of allogeneic, adipose-derived mesenchymal stem cells (AD-MSC) loaded with an oncolytic agent such as the vaccinia virus. Calidi’s research has shown the potential ability of the SNV-1 platform to shield the viral payload from the immune system, supporting efficient delivery to tumor sites and effectively potentiating oncolytic viruses.
“SuperNova-1 is the culmination of Calidi’s years of research into the powerful capabilities of stem cells as a delivery and potentiation platform for oncolytic viruses,” said Allan J. Camaisa, CEO and Chairman of Calidi Biotherapeutics. “We look forward to seeing this partnership with GenScript ProBio increase distribution of our enhanced oncolytic virotherapy delivery technology for potential therapeutic treatments of multiple cancer indications.”
GenScript ProBio will promote SNV-1 to current, prospective, and future clients or third parties who may benefit from the product—in addition to negotiating potential manufacturing and licensing agreements with interested parties.
“The SuperNova-1 product indicates exciting potential for the future of cancer treatment,” said Brian Hosung Min, CEO of GenScript ProBio. “With our expertise in global sales and distribution organization, this partnership is well-poised to generate global growth around Calidi’s revolutionary technology.”
GenScript ProBio will pay Calidi a low double-digit percentage of the net revenue produced by its SNV-1 manufacturing services per the agreement reached.
